China's NMPA approved Suriqioleucel on June 22, 2026, making it the first CAR-T therapy cleared anywhere in the world for advanced end-stage gastric cancer. Priced at 990,000 RMB per dose, the drug more than doubled median survival in clinical trials, from 3.98 months to 9.17 months.

Subscribe to read everything on GATE86
Already a subscriber? Log in

